Cipla navigated a challenging quarter marked by the completion of generic Revlimid decline and supply disruptions, while executing strategic growth initiatives including partnerships with Pfizer, acquisition of Inzpera, and successful product launches in diabetes care.
vs Q4 FY26
| Metric | Value | YoY |
|---|---|---|
| Total Revenue | ₹7.1K Cr | 0% YoY |
| EBITDA Margin | 17.7 percentage | 0% YoY |
| Profit After Tax | ₹676 Cr | 0% YoY |
| R&D Investment | ₹494 Cr | +37.4% YoY |
| Net Cash Balance | ₹10K Cr | 0% YoY |
| One India Business Growth | 10 percentage | 0% YoY |
| Metric | Latest | Trend |
|---|---|---|
| Total Revenue(crores) | 7074 | |
| Q4 Revenue(crores) | 6541 | |
| Q4 EBITDA Margin(percentage) | 15.2 | |
| Q4 PAT(crores) | 555 | |
| One India Revenue(crores) | 3000 | |
| EBITDA Margin(percentage) | 17.7 |
| Category | Target | Priority |
|---|---|---|
| FY26 EBITDA Margin | EBITDA Margin→Around 21% | Medium |
| Lanreotide Supply Recovery | Production Restart→H1 FY27 | Medium |
| Severity | Risk |
|---|---|
high | Lanreotide Supply Disruption Pharmathen facility received 9 FDA observations, production paused, expected restart in H1 FY27 Other |
high | Generic Revlimid Revenue Completion Major revenue decline completed this quarter, no meaningful contribution expected Other |
medium | Increased R&D Expenditure 37.4% YoY increase in R&D spend, focused on oligonucleotides and complex generics Other |
Umang Vohra officially transitioned leadership responsibilities to Achin Gupta, marking the completion of planned succession. Achin emphasized continuity in strategy while preparing for next phase of growth.
Major strategic moves including partnership with Pfizer for four established brands, acquisition of Inzpera Health Sciences for pediatric portfolio, and successful launches of Afrezza and Yurpeak in diabetes care.
Lanreotide supply significantly impacted due to partner Pharmathen's FDA inspection resulting in 9 observations and production halt. Expected resolution in H1 FY27 with exploration of alternate manufacturing sites.
One India business delivered robust 10% YoY growth with respiratory franchise crossing Rs 5,000 crores milestone. Strong performance across chronic care segments with respiratory, diabetes, and cardiac therapies showing double-digit growth.